Synaire Secures Tens of Millions in Angel Funding to Build the 'Dyson of Respiratory Devices'

VCBeat has learned that Synaire, an emerging medical technology company specializing in the R&D of intelligent respiratory therapy devices, recently announced the completion of its angel financing round, raising tens of millions of RMB. The round was led by Huagai Capital, with participation from joymed and Hefei Binhu Financial Investment. Ruohua Capital served as the exclusive long-term financial advisor. The funds will be primarily allocated to core product development, clinical validation, regulatory registration, and global brand expansion.

Ventilators are undergoing a dual transformation driven by “AI intelligence” and “home-based scenarios.” The industry remains dominated by traditional engineering-focused foreign brands, such as ResMed and Philips, while the Chinese market is saturated with low-priced, homogeneous products. Synaire has chosen a distinctly different path by focusing on foundational technological innovation and product definition.

If Dyson disrupted the vacuum cleaner and hair dryer markets, Synaire is redefining the home ventilator, a traditional medical device. Its inaugural product integrates “technological performance” with “ultimate aesthetics,” catering to both home and travel scenarios. It features AI intelligence, physiological closed-loop control, a modular structure, and stylish design:

• The world’s smallest AI-powered ventilator, with a book-like design suitable for travel and bedside use, featuring modular expandability for accessories such as humidifiers and batteries;

Conceptual Diagram of a Modular Ventilator

• Proprietary physiological closed-loop algorithm that monitors SpO₂, heart rate, and respiratory rate in real time, with dynamic automatic parameter adjustment to achieve truly “personalized therapy”;

Schematic Diagram of Physiological Closed-Loop Control

• Innovative sponge-free blower system utilizing advanced noise-reduction technology, which completely eliminates the health risks associated with traditional polyurethane foam (PUF) and has a clear pathway for FDA registration;

• Featuring the latest high-performance blower technology, deeply integrated with AI algorithms to deliver control precision and comfort on par with ResMed.

Synaire focuses on the mid-to-high-end market segment, which is currently monopolized by brands such as ResMed. By adopting a strategy of “high-end performance at mid-range prices,” Synaire has rapidly entered the market. It initially targets B2B channels (hospitals, pharmacies, and insurance providers) and gradually penetrates the B2C home consumer market, thereby establishing a brand evolution path that progresses from professional use to consumer adoption.

While establishing a strong foothold in China, Synaire is simultaneously expanding into international markets, with plans to complete CE and FDA regulatory approvals by early 2026 and establish a marketing network covering core markets in Europe and the United States. The company has assembled a core team with extensive international experience, comprising professionals from leading enterprises such as Mindray, ResMed, Philips, and Roche, who cover key areas including global product expansion, channel management, and direct-to-consumer (DTC) marketing.

During the initial launch phase, we will leverage resources from overseas sleep medicine centers, chain pharmacies, and online platforms to accelerate brand establishment and create a new paradigm for Chinese high-end medical brands expanding globally.

Zhang Yi, Managing Partner of Huagai Capital's Early-Stage FundIndicates:“Synaire’s sponge-free noise reduction technology is the only solution with FDA biocompatibility and 510(k) clearance potential in the post-Philips era, demonstrating technological leadership. Its physiological closed-loop algorithm propels ventilators into the ‘autonomous driving’ era, truly alleviating the burden on patients and physicians. We are optimistic about its global execution capabilities, positioning it to become a new benchmark for smart home medical devices.”

Cao Changqing, Chairman of joymedIndicates:“Synaire has accumulated profound expertise in the respiratory therapy sector and possesses the comprehensive capabilities to build a global high-end brand. We will support its rapid international expansion through our global supply chain and overseas resources, assisting it in effectively navigating uncertainties and policy risks in the international market.”